Ross Moat - 15 Jan 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF COMMERCIAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
15 Jan 2023
Net transactions value
-$1,571
Form type
4
Filing time
20 Mar 2023, 17:19:09 UTC
Previous filing
06 Sep 2022
Next filing
03 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Award $17,629 +1,844 +23% $9.56 10,008 15 Jan 2023 Direct F1
transaction KNSA Class A Common Share Options Exercise +994 +9.9% 11,002 16 Mar 2023 Direct F2
transaction KNSA Class A Common Share Tax liability $6,223 -543 -4.9% $11.46 10,459 16 Mar 2023 Direct
transaction KNSA Class A Common Share Options Exercise +2,137 +20% 12,596 20 Mar 2023 Direct F2
transaction KNSA Class A Common Share Tax liability $12,977 -1,167 -9.3% $11.12 11,429 20 Mar 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -994 -33% $0.000000 1,988 16 Mar 2023 Class A Common Share 994 Direct F2, F3
transaction KNSA Restricted Share Unit Options Exercise $0 -2,137 -100% $0.000000* 0 20 Mar 2023 Class A Common Share 2,137 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2022 to January 15, 2023. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).
F2 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F3 The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, March 16, 2021.
F4 The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs.